Canton Hathaway, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Canton Hathaway, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 20, 2022	SELL	$83.14 - $145.99 $71,500 - $125,551	-860 Reduced 14.68%	5,000 $729,000
Q1 2022 Apr 12, 2022	BUY	$110.08 - $142.92 $22,016 - $28,583	200 Added 3.53%	5,860 $695,000
Q4 2021 Jan 06, 2022	BUY	$99.73 - $148.48 $115,686 - $172,236	1,160 Added 25.78%	5,660 $780,000
Q1 2021 Apr 14, 2021	SELL	$64.07 - $91.75 $23,705 - $33,947	-370 Reduced 7.6%	4,500 $308,000
Q4 2020 Feb 03, 2021	BUY	$65.07 - $98.24 $24,075 - $36,348	370 Added 8.22%	4,870 $417,000
Q3 2020 Nov 09, 2020	BUY	$59.04 - $77.95 $106,272 - $140,310	1,800 Added 66.67%	4,500 $293,000
Q2 2020 Jul 27, 2020	BUY	$29.01 - $74.23 $78,327 - $200,421	2,700 New	2,700 $197,000
Q1 2020 May 06, 2020	SELL	$27.51 - $57.29 $82,530 - $171,870	-3,000 Closed	0 $0
Q4 2019 Jan 10, 2020	BUY	$40.86 - $57.65 $40,860 - $57,650	1,000 Added 50.0%	3,000 $163,000
Q3 2019 Oct 11, 2019	BUY	$37.38 - $49.47 $74,760 - $98,940	2,000 New	2,000 $83,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Canton Hathaway, LLC, based on Form 13F filings with the SEC.

Stay updated on Canton Hathaway, LLC with notifications on news.